https://médecine.top/index.php?action=history&feed=atom&title=Syndrome_h%C3%A9pator%C3%A9nal 2026-09-04T04:58:45Z Historique des révisions pour cette page sur le wiki MediaWiki 1.35.2 https://médecine.top/index.php?title=Syndrome_h%C3%A9pator%C3%A9nal&diff=1059&oldid=prev 2020-04-19T14:17:53Z

<p></p> <table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr class="diff-title" lang="fr"> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Version précédente</td> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Version du 19 avril 2020 à 14:17</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l15" >Ligne 15 :</td> <td colspan="2" class="diff-lineno">Ligne 15 :</td></tr> <tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* La mortalité associée est plus basse que pour le SHR de type 1, avec une survie médiane de 6 mois.&lt;ref&gt;https://www.revmed.ch/RMS/2019/RMS-N-639/Syndrome-hepatorenal-quoi-de-neuf#tab2&lt;/ref&gt;</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* La mortalité associée est plus basse que pour le SHR de type 1, avec une survie médiane de 6 mois.&lt;ref&gt;https://www.revmed.ch/RMS/2019/RMS-N-639/Syndrome-hepatorenal-quoi-de-neuf#tab2&lt;/ref&gt;</div></td></tr> <tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td></tr> <tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">== Traitement ==</ins></div></td></tr> <tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">Treatment of HRS involves withdrawal of diuretics, volume expansion, with intravenous albumin, and vasoconstrictors. Treatment may also include midodrine and octreotide with intravenous albumin to raise mean arterial pressure and improve kidney perfusion. Hemodialysis while awaiting liver transplantation may be required for patients whose kidney function does not improve with therapy.&lt;ref&gt;https://mksap18.acponline.org/app/topics/gi/mk18_a_gi_s6/mk18_a_gi_s6_10_7&lt;/ref&gt;</ins></div></td></tr> <tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>== Références ==</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>== Références ==</div></td></tr> </table>

Julien https://médecine.top/index.php?title=Syndrome_h%C3%A9pator%C3%A9nal&diff=1058&oldid=prev 2020-04-19T14:17:08Z

<p></p> <table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr class="diff-title" lang="fr"> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Version précédente</td> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Version du 19 avril 2020 à 14:17</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l14" >Ligne 14 :</td> <td colspan="2" class="diff-lineno">Ligne 14 :</td></tr> <tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* Généralement pas de facteur précipitant.</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* Généralement pas de facteur précipitant.</div></td></tr> <tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* La mortalité associée est plus basse que pour le SHR de type 1, avec une survie médiane de 6 mois.&lt;ref&gt;https://www.revmed.ch/RMS/2019/RMS-N-639/Syndrome-hepatorenal-quoi-de-neuf#tab2&lt;/ref&gt;</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* La mortalité associée est plus basse que pour le SHR de type 1, avec une survie médiane de 6 mois.&lt;ref&gt;https://www.revmed.ch/RMS/2019/RMS-N-639/Syndrome-hepatorenal-quoi-de-neuf#tab2&lt;/ref&gt;</div></td></tr> <tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;"></ins></div></td></tr> <tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">== Références ==</ins></div></td></tr> </table>

Julien https://médecine.top/index.php?title=Syndrome_h%C3%A9pator%C3%A9nal&diff=1057&oldid=prev 2020-04-19T14:16:44Z

<p><span dir="auto"><span class="autocomment">Classification</span></span></p> <table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr class="diff-title" lang="fr"> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Version précédente</td> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Version du 19 avril 2020 à 14:16</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l6" >Ligne 6 :</td> <td colspan="2" class="diff-lineno">Ligne 6 :</td></tr> <tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>== Classification ==</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>== Classification ==</div></td></tr> <tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>=== Type 1 ===</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>=== Type 1 ===</div></td></tr> <tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div> </div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins class="diffchange diffchange-inline">* Caractérisé par une augmentation rapide des valeurs de créatinine, sans seuil défini.</ins></div></td></tr> <tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins class="diffchange diffchange-inline">* On retrouve fréquemment un facteur précipitant.</ins></div></td></tr> <tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins class="diffchange diffchange-inline">* La mortalité associée est très élevée : 90 % à 10 jours sans traitement.</ins></div></td></tr> <tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>=== Type 2 ===</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>=== Type 2 ===</div></td></tr> <tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">* Caractérisé par une élévation progressive de la créatinine</ins></div></td></tr> <tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">* Ascite réfractaire aux diurétiques qui reflète l’évolution de la maladie cirrhotique.</ins></div></td></tr> <tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">* Généralement pas de facteur précipitant.</ins></div></td></tr> <tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">* La mortalité associée est plus basse que pour le SHR de type 1, avec une survie médiane de 6 mois.&lt;ref&gt;https://www.revmed.ch/RMS/2019/RMS-N-639/Syndrome-hepatorenal-quoi-de-neuf#tab2&lt;/ref&gt;</ins></div></td></tr> </table>

Julien https://médecine.top/index.php?title=Syndrome_h%C3%A9pator%C3%A9nal&diff=1056&oldid=prev 2020-04-19T14:12:10Z

<p><span dir="auto"><span class="autocomment">Définition</span></span></p> <table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr class="diff-title" lang="fr"> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Version précédente</td> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Version du 19 avril 2020 à 14:12</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l3" >Ligne 3 :</td> <td colspan="2" class="diff-lineno">Ligne 3 :</td></tr> <tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* Réduction du flux sanguin rénal avec dilatation splanchnique dans le contexte d&#039;hypertension portale</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* Réduction du flux sanguin rénal avec dilatation splanchnique dans le contexte d&#039;hypertension portale</div></td></tr> <tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* Présence de cirrhose la plupart du temps, [[hépatite alcoolique]] et hépatite fulminante plus rarement</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* Présence de cirrhose la plupart du temps, [[hépatite alcoolique]] et hépatite fulminante plus rarement</div></td></tr> <tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;"></ins></div></td></tr> <tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>== Classification ==</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>== Classification ==</div></td></tr> <tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>=== Type 1 ===</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>=== Type 1 ===</div></td></tr> <tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td></tr> <tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>=== Type 2 ===</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>=== Type 2 ===</div></td></tr> </table>

Julien https://médecine.top/index.php?title=Syndrome_h%C3%A9pator%C3%A9nal&diff=1055&oldid=prev 2020-04-19T14:11:54Z

<p>Page créée avec « <a href="/Cat%C3%A9gorie:Gastro-ent%C3%A9rologie" title="Catégorie:Gastro-entérologie">Category:Gastro-entérologie</a> == Définition == * Réduction du flux sanguin rénal avec dilatation splanchnique dans le contexte d&#039;hypertension portale * Présence de... »</p> <p><b>Nouvelle page</b></p><div>[[Category:Gastro-entérologie]]<br /> == Définition ==<br /> * Réduction du flux sanguin rénal avec dilatation splanchnique dans le contexte d&#039;hypertension portale<br /> * Présence de cirrhose la plupart du temps, [[hépatite alcoolique]] et hépatite fulminante plus rarement<br /> == Classification ==<br /> === Type 1 ===<br /> <br /> === Type 2 ===</div>

Julien